JBPHF (Jacobio Pharmaceuticals Group Co) Cash Conversion Cycle: -16,073.00 (As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.42
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Cash Conversion Cycle?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Cash Conversion Cycle is -16,073.00 as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.42. The stock has 6 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Jacobio Pharmaceuticals Group Co's Days Sales Outstanding for the six months ended in Dec. 2025 was 678.98.
Jacobio Pharmaceuticals Group Co's Days Inventory for the six months ended in Dec. 2025 was 0.
Jacobio Pharmaceuticals Group Co's Days Payable for the six months ended in Dec. 2025 was 16751.98.
Therefore, Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2025 was -16,073.00.


Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Jacobio Pharmaceuticals Group Co Cash Conversion Cycle Related Terms


Jacobio Pharmaceuticals Group Co Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Cash Conversion Cycle Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial -102.47 -334.69 -491.22 20.16 -47,997.68

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -590.35 0.00 9.00 116.17 -16,073.00

JBPHF vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co Cash Conversion Cycle vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=55.64+0-48053.32
=-47,997.68

Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=678.98+0-16751.98
=-16,073.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of -16,073.00 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Cash Conversion Cycle of -16,073.00 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle too high?
Jacobio Pharmaceuticals Group Co's current Cash Conversion Cycle is -16,073.00. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Cash Conversion Cycle of -16,073.00 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.45, based on 873 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Cash Conversion Cycle is -16,073.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Cash Conversion Cycle of -16,073.00. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current Cash Conversion Cycle is -16,073.00. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Cash Conversion Cycle is -16,073.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.

Key valuation signals for JBPHF:

  • Cash Conversion Cycle: -16,073.00
  • GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.42
GF Value